Lamivudine Sandoz

Lamivudine, the active ingredient in Lamivudine Sandoz, is a nucleoside reverse transcriptase inhibitor presented as a tablet for oral use. It treats HIV infection and chronic hepatitis B in adult patients. It works by interfering with viral replication, helping to reduce viral load and improve immune function.

GNH USA supplies Lamivudine Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures reliable and timely delivery and regulatory compliance across multiple global regions.

Lamivudine is a nucleoside reverse transcriptase inhibitor used in the management of viral infections.

- HIV infection: Reduces viral replication and improves immune parameters in adults living with HIV. - Chronic hepatitis B: Suppresses hepatitis B virus replication, helping to prevent disease progression. - Prevention of mother‑to‑child transmission of HIV: Decreases the risk of vertical transmission when used in pregnant women.

Lamivudine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: Mild to moderate upset stomach. - Headache: Transient cranial discomfort. - Fatigue: Generalized tiredness. - Diarrhea: Loose stools, usually self‑limiting.

Serious or Rare Side Effects: - Lactic acidosis: Accumulation of lactate leading to metabolic disturbance. - Severe hepatomegaly with steatosis: Marked liver enlargement and fat accumulation. - Stevens‑Johnson syndrome: Rare severe skin reaction requiring immediate medical attention.

Before initiating therapy, several safety considerations should be observed.

- Monitor liver function: Perform baseline and periodic hepatic enzyme tests. - Assess renal function: Adjust dose in patients with impaired clearance. - Counsel on adherence: Emphasize the importance of consistent dosing to prevent resistance. - Avoid concurrent use with didanosine: Increases risk of pancreatitis. - Use with caution in pregnancy: Limited data, weigh benefits against potential risks. - Store at below 25°C: Keep in original packaging, protect from moisture.

Lamivudine can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Didanosine: Co‑administration raises risk of pancreatitis. - Stavudine: Combined use may enhance mitochondrial toxicity. - Other NRTIs with overlapping toxicity: May increase risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Protease inhibitors (e.g., ritonavir): May require dose adjustment of lamivudine. - Nephrotoxic agents (e.g., tenofovir): Monitor renal function closely. - Alcohol: May exacerbate hepatic side effects.